Moxifloxacin hydrochloride
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1999
- First approval year
- 1999
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Moxifloxacin hydrochloride
- Molecular weight
- 437.9
- Structure (SMILES)
- COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12.Cl
- avelox
- Avelox
- minims
- Minims
- moxeza
- Moxeza
- moxifloxacin hydrochloride
- Moxifloxacin hydrochloride
- moxivig
- Moxivig
- vigamox
- Vigamox
- (4AS-CIS)-1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-8-METHOXY-7-(OCTAHYDRO-6H-PYRROLOL(3,4-B)PYRIDIN-6-YL)-4-OXO-3-QUINOLINECARBOXYLIC ACID, MONOHYDROCHLORIDE
- 1 cyclopropyl 6 fluoro 1 4 dihydro 8 methoxy 7 4as 7as octahydro 6h pyrrolo 3 4 b pyridin 6 yl 4 oxo 3 quinolinecarboxylic acid monohydrochloride
- 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid, monohydrochloride
- 4as cis 1 cyclopropyl 6 fluoro 1 4 dihydro 8 methoxy 7 octahydro 6h pyrrolol 3 4 b pyridin 6 yl 4 oxo 3 quinolinecarboxylic acid monohydrochloride
- al 15469a
- AL-15469A
- bay 12 8039
- BAY 12-8039
- BAY-12-8039
- minims
- Moxifloxacin (as hydrochloride)
- moxifloxacin 0 5 ophthalmic solution vigamox
- Moxifloxacin 0.5% ophthalmic solution (Vigamox)
- moxifloxacin as hydrochloride
- moxifloxacin hcl
- Moxifloxacin hcl
- MOXIFLOXACIN HCL [VANDF]
- moxifloxacin hcl vandf
- moxifloxacin hydrochloride
- Moxifloxacin hydrochloride
- MOXIFLOXACIN HYDROCHLORIDE [EP MONOGRAPH]
- MOXIFLOXACIN HYDROCHLORIDE [JAN]
- MOXIFLOXACIN HYDROCHLORIDE [MART.]
- MOXIFLOXACIN HYDROCHLORIDE [MI]
- MOXIFLOXACIN HYDROCHLORIDE [ORANGE BOOK]
And 19 more, listed on the interactive page.
- CAS registry numbers
- 186826-86-8
- ChEMBL ID
- CHEMBL1200735
- InChIKey
- IDIIJJHBXUESQI-DFIJPDEKSA-N
- FDA ingredient codes (UNII)
- C53598599T
- Applicant
- HARROW EYE
- Approval date
- 15 Apr 2003
- Application number
- NDA021598
- Patents
- 2
- Designations
- 1
- Earliest recorded loss of exclusivity
- 29 May 2029
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Drug name stem
- -oxacin
Administration routes
- Oral
- Parenteral
- topical
- Mechanism
- Bacterial DNA gyrase inhibitor
- Action type
- Inhibitor
- Target
- Bacterial DNA gyrase
- Protein identifier
- P0AES4
- Mechanism
- Bacterial DNA gyrase inhibitor
- Action type
- Inhibitor
- Target
- Bacterial DNA gyrase
- Protein identifier
- P0AES6
- Mechanism
- Topoisomerase IV inhibitor
- Action type
- Inhibitor
- Target
- Topoisomerase IV
- Protein identifier
- P0AFI2
- Mechanism
- Topoisomerase IV inhibitor
- Action type
- Inhibitor
- Target
- Topoisomerase IV
- Protein identifier
- P20083
- Mechanism
- Bacterial DNA gyrase inhibitor
- Action type
- Inhibitor
- Target
- Bacterial DNA gyrase
- Mechanism
- Topoisomerase IV inhibitor
- Action type
- Inhibitor
- Target
- Topoisomerase IV
- Condition
- Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Osteomyelitis
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0003102
- Subject identifier
- D010019
- Condition
- Pneumonia
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003106
- Subject identifier
- D011014
- Condition
- Lung Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003818
- Subject identifier
- D008171
- Condition
- Communicable Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005741
- Subject identifier
- D003141
- Condition
- Bronchitis, Chronic
- Highest recorded phase
- 4
- Condition identifier
- EFO:0006505
- Subject identifier
- D029481
- Condition
- Sinusitis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0007486
- Subject identifier
- D012852
- Condition
- Conjunctivitis, Bacterial
- Highest recorded phase
- 4
- Condition identifier
- EFO:1000829
- Subject identifier
- D003234
- Condition
- Pelvic Inflammatory Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001388
- Subject identifier
- D000292
- Condition
- Corneal Ulcer
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004577
- Subject identifier
- D003320
- Condition
- Cataract
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005129
- Subject identifier
- D002386
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Cystic Fibrosis
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0009061
- Subject identifier
- D003550
- Condition
- Graft vs Host Disease
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0013730
- Subject identifier
- D006086
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 4
- Condition identifier
- EFO_0003102
- Condition identifier
- EFO_0003106
- Condition identifier
- EFO_0003818
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005741
- Highest recorded phase
- 3
- Condition identifier
- EFO_0006505
- Condition identifier
- EFO_0007315
- Condition identifier
- EFO_0007486
- Condition identifier
- EFO_0009449
- Condition identifier
- EFO_0009450
- Condition identifier
- EFO_0009536
- Condition identifier
- EFO_1000829
- Condition identifier
- EFO_1001388
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0003085
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0003799
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004577
- Condition identifier
- MONDO_0004577
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004785
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005129
- Condition identifier
- MONDO_0005249
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005607
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005800
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005961
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0006668
- Highest recorded phase
- 4
And 4 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Warning
- Black Box Warning
- Effect
- musculoskeletal toxicity
- Warning
- Black Box Warning
- Effect
- neurotoxicity
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- musculoskeletal toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- neurotoxicity
- Country
- United States
- Event
- anaphylactic reaction
- Reports
- 997
- Reporting signal score
- 1,151.3
- Event
- anaphylactic shock
- Reports
- 239
- Reporting signal score
- 369.642
- Event
- choroiditis
- Reports
- 42
- Reporting signal score
- 149.233
- Event
- contrast media allergy
- Reports
- 94
- Reporting signal score
- 315.413
- Event
- corneal oedema
- Reports
- 68
- Reporting signal score
- 160.148
- Event
- delirium
- Reports
- 165
- Reporting signal score
- 143.948
- Event
- dizziness
- Reports
- 686
- Reporting signal score
- 207.486
- Event
- drug hypersensitivity
- Reports
- 3,106
- Reporting signal score
- 3,255.72
- Event
- dyspnoea
- Reports
- 862
- Reporting signal score
- 296.949
- Event
- electrocardiogram qt prolonged
- Reports
- 489
- Reporting signal score
- 408.414
- Event
- endophthalmitis
- Reports
- 99
- Reporting signal score
- 188.903
- Event
- hypersensitivity
- Reports
- 1,019
- Reporting signal score
- 577.732
- Event
- iris transillumination defect
- Reports
- 48
- Reporting signal score
- 237.793
- Event
- mental disorder
- Reports
- 143
- Reporting signal score
- 167.608
- Event
- musculoskeletal injury
- Reports
- 35
- Reporting signal score
- 149.253
- Event
- myalgia
- Reports
- 873
- Reporting signal score
- 381.569
- Event
- paraesthesia
- Reports
- 778
- Reporting signal score
- 381.596
- Event
- pruritus
- Reports
- 1,171
- Reporting signal score
- 415.147
- Event
- rash
- Reports
- 1,801
- Reporting signal score
- 560.643
- Event
- swelling face
- Reports
- 199
- Reporting signal score
- 155.634
- Event
- tendon disorder
- Reports
- 316
- Reporting signal score
- 761.135
- Event
- tendon pain
- Reports
- 580
- Reporting signal score
- 1,807.94
- Event
- tendon rupture
- Reports
- 556
- Reporting signal score
- 1,259.57
- Event
- tendonitis
- Reports
- 847
- Reporting signal score
- 2,156.3
- Event
- torsade de pointes
- Reports
- 111
- Reporting signal score
- 166.826
And 3 more, listed on the interactive page.
- NCT00312338
- NCT00332293
- NCT00798577
- NCT01238783
- NCT02980523
- NCT00324324
- NCT00769171
- NCT00431678
- NCT00665327
- NCT00717561
- NCT00473460
- NCT00656747
- NCT00683865
- NCT00824070
- NCT00828971
- NCT01910415
- NCT01928693
- NCT02099240
- NCT03405168
- NCT04204122
- Dose
- 400 mg
- Route
- Oral
- How often
- Once daily
- Drink fluids liberally
- Take with or without food
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 2
- Polar surface area
- 83.8
- Calculated partition coefficient (ALogP)
- 2.37
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 30
- Molecular formula
- C21H25ClFN3O4
- Monoisotopic mass
- 437.1517621
- Natural product
- No
- 0781-7135
- 0832-1410
- 0904-7407
- 16714-643
- 31722-845
- 33342-322
- 46708-505
- 50268-576
- 55111-112
- 57237-156
- 62135-014
- 62332-505
- 63323-850
- 65862-603
- 65862-840
- 67457-323
- 68083-210
- 68084-722
- 68180-421
- 70069-081
- 70756-638
- 72189-334
- 72266-158
- 72789-037
- 72789-038
And 21 more, listed on the interactive page.
- Recorded assays
- 1,024
- Active assays
- 50
- Confirmatory
- Screening
- Summary
- Anti-Bacterial Agents
- Topoisomerase II Inhibitors
Related records
Trials (54)
- 2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery
- A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms
- A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.
- A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.
- A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates
- A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects
- A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis
- A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery
- AL-15469A for the Treatment of Bacterial Conjunctivitis
- Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects
- Bioequivalence of Eye Drops and Spray Administration of Vigamox
- Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
- Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
- Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
- Determining the Effect of Antibiotic Drop Prophylaxis on the Conjunctival Flora
- Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections
- Dropless Pars Plana Vitrectomy Study
- Dropless vs. Standard Drops Contralateral Eye Study
- Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision
Approved for (4)
- Bacterial conjunctivitis
- Chronic bronchitis
- Pneumonia
- Sinusitis
In development for (9)
- Breast cancer Phase 2
- Cataract Phase 1
- Corneal ulcer Phase 2
- Cystic fibrosis Phase 1
- Graft versus host disease Phase 2
- Infectious disease Phase 3
- Lung disorder Phase 3
- Osteomyelitis Early phase 1
- Pelvic inflammatory disease Phase 3
Other linked conditions (4)
- Blepharitis
- Conjunctivitis
- Keratitis
- Skin disease caused by bacterial infection